Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 277.2 SEK -1.84%
Market Cap: kr8.7B

EV/OCF

84.6
Current
47%
Cheaper
vs 3-y average of 160.6

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
84.6
=
Enterprise Value
kr8.6B
/
Operating Cash Flow
kr101.1m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
84.6
=
Enterprise Value
kr8.6B
/
Operating Cash Flow
kr101.1m

Valuation Scenarios

Xvivo Perfusion AB is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (160.6), the stock would be worth kr526.02 (90% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-82%
Maximum Upside
+90%
Average Downside
13%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 84.6 kr277.2
0%
3-Year Average 160.6 kr526.02
+90%
5-Year Average 103.3 kr338.46
+22%
Industry Average 15.2 kr49.71
-82%
Country Average 15.9 kr52
-81%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close

Market Distribution

Higher than 96% of companies in Sweden
Percentile
96th
Based on 1 211 companies
96th percentile
84.6
Low
0.3 — 10.7
Typical Range
10.7 — 23.7
High
23.7 —
Distribution Statistics
Sweden
Min 0.3
30th Percentile 10.7
Median 15.9
70th Percentile 23.7
Max 9 494.9

Xvivo Perfusion AB
Glance View

Market Cap
8.7B SEK
Industry
Health Care

Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted. Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.

XVIVO Intrinsic Value
261.55 SEK
Overvaluation 6%
Intrinsic Value
Price kr277.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett